The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Hypertension, Malignant

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hypertension, Malignant


High impact information on Hypertension, Malignant


Chemical compound and disease context of Hypertension, Malignant


Biological context of Hypertension, Malignant


Anatomical context of Hypertension, Malignant


Gene context of Hypertension, Malignant


Analytical, diagnostic and therapeutic context of Hypertension, Malignant


  1. Plasma renin activity and hypertension in diabetes mellitus. Christlieb, A.R., Kaldany, A., D'Elia, J.A. Diabetes (1976) [Pubmed]
  2. Variable response to oral angiotensin-converting-enzyme blockade in hypertensive scleroderma patients. Whitman, H.H., Case, D.B., Laragh, J.H., Christian, C.L., Botstein, G., Maricq, H., Leroy, E.C. Arthritis Rheum. (1982) [Pubmed]
  3. Rapid development of nephrotic syndrome, hypertension, and hemolytic anemia early in pregnancy in patients with IDDM. Weinstock, R.S., Kopecky, R.T., Jones, D.B., Sunderji, S. Diabetes Care (1988) [Pubmed]
  4. Clinical pharmacokinetics of vasodilators. Part I. Kirsten, R., Nelson, K., Kirsten, D., Heintz, B. Clinical pharmacokinetics. (1998) [Pubmed]
  5. Anterior ischemic optic neuropathy. VIII. Clinical features and pathogenesis of post-hemorrhagic amaurosis. Hayreh, S.S. Ophthalmology (1987) [Pubmed]
  6. Blood pressure in acute and chronic vasopressin excess: studies of malignant hypertension and the syndrome of inappropriate antidiuretic hormone secretion. Padfield, P.L., Brown, J.J., Lever, A.F., Morton, J.J., Robertson, J.I. N. Engl. J. Med. (1981) [Pubmed]
  7. Minoxidil treatment of malignant hypertension. Recovery of renal function. Luft, F.C., Bloch, R., Szwed, J.J., Grim, C.M., Grim, C.E. JAMA (1978) [Pubmed]
  8. Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. Cozza, E.N., Gomez-Sanchez, C.E., Foecking, M.F., Chiou, S. J. Clin. Invest. (1989) [Pubmed]
  9. Phlebotomy for erythropoietin-associated malignant hypertension. Fahal, I.H., Yaqoob, M., Ahmad, R. Lancet (1991) [Pubmed]
  10. The promise of computerized feedback systems for diabetes care. McDonald, C.J., Overhage, J.M., Tierney, W.M., Abernathy, G.R., Dexter, P.R. Ann. Intern. Med. (1996) [Pubmed]
  11. Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor captopril. Case, D.B., Atlas, S.A., Sullivan, P.A., Laragh, J.H. Circulation (1981) [Pubmed]
  12. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Gavras, H., Brunner, H.R., Laragh, J.H., Vaughan, E.D., Koss, M., Cote, L.J., Gavras, I. Circ. Res. (1975) [Pubmed]
  13. The failure of furosemide-induced salt and water loss to convert benign to malignant hypertension in the rat. Wilson, S.K., Solez, K., Heptinstall, R.H. Am. J. Pathol. (1980) [Pubmed]
  14. Hemodynamic mechanism of blood pressure response to captopril in human malignant hypertension. Saragoça, M.A., Homsi, E., Ribeiro, A.B., Ferreira Filho, S.R., Ramos, O.L. Hypertension (1983) [Pubmed]
  15. A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial dysfunction in malignant phase hypertension. Lip, G.Y., Edmunds, E., Hee, F.L., Blann, A.D., Beevers, D.G. Am. J. Hypertens. (2001) [Pubmed]
  16. Platelet-derived growth factor gene expression in the kidney of malignant hypertension. Okamura, M., Konishi, Y., Nishimura, M., Negoro, N., Umetani, N., Inoue, T., Kanayama, Y., Takeda, T. Blood pressure. Supplement. (1992) [Pubmed]
  17. Malignant hypertension - the role of the paracrine renin-angiotensin system. Fleming, S. J. Pathol. (2000) [Pubmed]
  18. Comparison of effect of endothelin antagonism and angiotensin-converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with N omega-nitro-L-arginine methyl ester. Correlation with topography of vascular endothelin-1 gene expression. Li, J.S., Deng, L.Y., Grove, K., Deschepper, C.F., Schiffrin, E.L. Hypertension (1996) [Pubmed]
  19. Alterations in intracellular cations and cell membrane ATPase activity in patients with malignant hypertension. Touyz, R.M., Milne, F.J. J. Hypertens. (1995) [Pubmed]
  20. Cerebrospinal fluid lactate and pyruvate concentrations in patients with malignant hypertension. Fujishima, M., Nakatomi, Y., Tamaki, K., Ishitsuka, T., Kawasaki, T., Omae, T. J. Neurol. (1984) [Pubmed]
  21. Increased production of angiotensin II in the adrenal gland of stroke-prone spontaneously hypertensive rats with malignant hypertension. Kim, S., Hosoi, M., Shimamoto, K., Takada, T., Yamamoto, K. Biochem. Biophys. Res. Commun. (1991) [Pubmed]
  22. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Schiffrin, E.L., Sventek, P., Li, J.S., Turgeon, A., Reudelhuber, T. Br. J. Pharmacol. (1995) [Pubmed]
  23. Renoprotective effects of a combined endothelin type A/type B receptor antagonist in experimental malignant hypertension. Kohno, M., Yokokawa, K., Yasunari, K., Kano, H., Minami, M., Ueda, M., Tatsumi, Y., Yoshikawa, J. Metab. Clin. Exp. (1997) [Pubmed]
  24. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. Fu, M.L., Herlitz, H., Schulze, W., Wallukat, G., Micke, P., Eftekhari, P., Sjögren, K.G., Hjalmarson, A., Müller-Esterl, W., Hoebeke, J. J. Hypertens. (2000) [Pubmed]
  25. ANG II stimulates phospholipase D through PKCzeta activation in VSMC: implications in adhesion, spreading, and hypertrophy. Parmentier, J.H., Pavicevic, Z., Malik, K.U. Am. J. Physiol. Heart Circ. Physiol. (2006) [Pubmed]
  26. Response of arterial blood pressure, plasma renin activity and plasma aldosterone concentration to long-term administration of captopril in patients with severe, treatment-resistant malignant hypertension. McCaa, C.S., Langford, H.G., Cushman, W.C., McCaa, R.E. Clin. Sci. (1979) [Pubmed]
  27. Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. Montgomery, H.E., Kiernan, L.A., Whitworth, C.E., Fleming, S., Unger, T., Gohlke, P., Mullins, J.J., McEwan, J.R. J. Hypertens. (1998) [Pubmed]
  28. Renal haemodynamics and comparative effects of captopril in patients with benign- or malignant-essential hypertension, or with chronic renal failure. Shionoiri, H., Yasuda, G., Takagi, N., Oda, H., Young, S.C., Miyajima, E., Umemura, S., Gotoh, E., Sesoko, S., Uneda, S. Clinical and experimental hypertension. Part A, Theory and practice. (1987) [Pubmed]
  29. Spontaneous renal artery dissection. Perry, M.O. The Journal of cardiovascular surgery. (1982) [Pubmed]
  30. Changes of plasma renin, angiotensin II and renin substrate during reversal of malignant renovascular hypertension. Schultze, G., Oelkers, W. Klin. Wochenschr. (1975) [Pubmed]
WikiGenes - Universities